Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and GIP , may represent a promising step forward for obesity loss . Preliminary clinical trials have shown considerable https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026